Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer

Current Opinion in Urology

Volumn 22, Issue 5, 2012, Pages 415-420

  Rodríguez Faba, Oscar ^a   Palou, Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GALECTIN 3; PROFILIN; PROTEIN PROFILIN 1; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DRUG DOSE COMPARISON; HIGH RISK PATIENT; HUMAN; LYMPH VESSEL METASTASIS; MEDLINE; PREDICTION; PRIORITY JOURNAL; REVIEW; TRANSURETHRAL RESECTION;

BCG VACCINE; CYSTECTOMY; DISEASE PROGRESSION; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84864831431     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328356ac20     Document Type: Review

References (45)

1. Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011; 186:2158-2167.
2. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-475. (Pubitemid 43259554)
3. Network NCC: ciinical practice guideliness in oncology: bladder cancer including upper tract tumors and urothelial carcinoma of the prostate. Version 2. Jenkintown. Pennsylvania. NCCN 2010. http://www.ncc.org 2010. [Accessed 27 March 2010]
4. Association AU: guideline for the management of nonmuscle invasive bladder cancer (stages Ta,T1, and Tis). http://www.auanet.org 2010. [Accessed 18 February 2010]
5. Palou J, Sylvester RJ, Rodriguez Faba O, et al. Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guerin. Eur Urol 2012; 62:118-125.
6. Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007; 177:1283-1286. (Pubitemid 46435978)
7. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53:992-1001.
8. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009; 182:2195-2203.
9. Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with nonmuscleinvasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol 2011; 60:423-430.
10. Castelao JE, Yuan JM, Skipper PL, et al. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 2001; 93:538-545. (Pubitemid 32318433)
11. Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stageadjusted bladder cancer survival. Urology 2000; 55:876-880. (Pubitemid 30330791)
12. Fajkovic H, Halpern JA, Cha EK, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011; 29:457-463.
13. Saint F, Patard JJ, Maille P, et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002; 167:364-367. (Pubitemid 34024586)
14. Poletajew S, Waledziak M, Fus L, et al. Urothelial bladder carcinoma in young patients is characterized by a relatively good prognosis. Ups J Med Sci 2012; 117:47-51.
15. Saint F, Salomon L, Quintela R, et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist?. analysis of a quarter century of literature. Eur Urol 2003; 43:351-360.
16. Takashi M, Wakai K, Hattori T, et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol 2002; 33:41-47. (Pubitemid 34575409)
17. Martinez-Pineiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer. BJU Int 2002; 89:671-680. (Pubitemid 34429530)
18. Joudi FN, Smith BJ, O'Donnell MA, et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 2006; 175:1634-1639.
19. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163:73-78.
20. Denzinger S, Otto W, Fritsche HM, et al. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol 2007; 14:995-999. (Pubitemid 47621840)
21. Alkhateeb SS, Van Rhijn BW, Finelli A, et al. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol 2010; 184:81-86.
22. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000; 163:68-71.
23. Herr HW, Badalament RA, Amato DA, et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141:22-29. (Pubitemid 19028816)
24. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164:680-684. (Pubitemid 30637601)
25. Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinomain situ: relationship of progression to histological response and p53 nuclear accumulation. J Urol 1997; 157:1655-1659. (Pubitemid 27171747)
26. Pansadoro V, Emiliozzi P, de Paula F, et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59:227-231. (Pubitemid 34134520)
27. Kakiashvili DM, van Rhijn BW, Trottier G, et al. Long-term follow-up of T1 highgrade bladder cancer after intravesical bacille Calmette-Guerin treatment. BJU Int 2011; 107:540-546.
28. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163:1124-1129. (Pubitemid 30169376)
29. Palou J, Xavier B, Laguna P, et al. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate. Urology 1996; 47:482-484.
30. Solsona E, Iborra I, Ricos JV, et al. The prostate involvement as prognostic factor in patients with superficial bladder tumors. J Urol 1995; 154:1710-1713.
31. Solsona E, Iborra I, Ricos JV, et al. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol 1996; 155:895-899.
32. Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; 164:685-689. (Pubitemid 30637602)
33. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41:523-531.
34. Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-nontreated patients. Eur Urol 2005; 48:231-238. (Pubitemid 40957095)
35. Cheng L, Montironi R, Davidson DD, et al. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009; 22 (Suppl 2):S70-S95.
36. Chang WC, Chang YH. Pan CC: Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection. Am J Surg Pathol 2012; 36:454-461.
37. van Rhijn BW, van der Kwast TH, Alkhateeb SS, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012; 61:378-384.
38. Algaba F. Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Curr Opin Urol 2006; 16:367-371. (Pubitemid 44231714)
39. Cho KS, Seo HK, Joung JY, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 2009; 182:2625-2630.
40. Streeper NM, Simons CM, Konety BR, et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int 2009; 103:475-479.
41. Resnick MJ, Bergey M, Magerfleisch L, et al. Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU Int 2011; 107:46-52.
42. Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, et al. Cathepsin e, maspin, plk1, and survivin are promising prognostic protein markers for progression in nonmuscle invasive bladder cancer. Am J Pathol 2012; 180:1824-1834.
43. Canesin G, Gonzalez-Peramato P, Palou J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010; 31:277-285.
44. Zoidakis J, Makridakis M, Zerefos PG et al.: Profilin 1 is a Potential Biomarker for Bladder Cancer Aggressiveness. Mol Cell Proteomics 2012; 11:M111009449.
45. Agundez M, Grau L, Palou J, et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours. Eur Urol 2011; 60:131-140.